RxDoctor Payments Data

Monica Zaki, DO

Neurology · Auburn Hills, MINPI 1992110134

Payments from drug & device makers

$21,257in general payments, 2019–2025

Across 1,200 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • Biogen$2K
  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Novartis$1K
  • EMD Serono, Inc.$971
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$1501%
  • Speaking & faculty fees$340%
  • Food & beverage$20,62697%
  • Education$4472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.116$1,755
Biogen83$1,705
AbbVie(2 entities)74$1,140
Teva Pharmaceuticals USA, Inc.64$1,122
Novartis83$1,013
EMD Serono, Inc.63$971
Neurocrine Biosciences, Inc.44$954
Jazz Pharmaceuticals Inc.52$932
Amgen(2 entities)45$839
Bristol Myers Squibb51$771
Johnson & Johnson36$672
Harmony Biosciences LLC37$611
Sanofi29$607
SK Life Science, Inc.26$577
Lilly USA, LLC32$531
Pfizer36$462
Lundbeck LLC28$448
Avanir Pharmaceuticals, Inc.24$430
Eisai Inc.15$424
Neurelis, Inc.17$346
Genentech USA, Inc.19$327
Axsome Therapeutics, Inc.18$289
Catalyst Pharmaceuticals, Inc.8$283
Vanda Pharmaceuticals Inc.11$272
Greenwich Biosciences, Inc.7$248
Acadia Pharmaceuticals Inc11$233
Kyowa Kirin, Inc.12$224
Upsher-smith Laboratories LLC12$216
Biohaven Pharmaceuticals, Inc.10$199
Otsuka America Pharmaceutical, Inc.10$196
Amneal Pharmaceuticals LLC8$168
E.r. Squibb & Sons, L.L.C.10$151
Sumitomo Pharma America, Inc.8$145
Adamas Pharmaceuticals, Inc.7$144
Argenx US, Inc.6$131
AstraZeneca(2 entities)6$131
Avadel CNS Pharmaceuticals, LLC6$127
Scilex Pharmaceuticals Inc.6$115
TG Therapeutics, Inc.4$113
Corium, LLC7$110
Banner Life Sciences, LLC2$95
Takeda Pharmaceuticals U.S.A., Inc.6$90
Aucta Pharmaceuticals, Inc.7$85
Sunovion Pharmaceuticals Inc.5$77
MDD US Operations, LLC4$74
Biohaven Pharmaceutical Holding Company Ltd.4$71
Novo Nordisk1$71
Acorda Therapeutics, Inc3$57
Cycle Pharmaceuticals Inc2$51
Avion Pharmaceuticals3$51
Medtronic(2 entities)2$48
Resmed Corp2$46
Sanofi-aventis U.S. LLC2$40
Azurity Pharmaceuticals, Inc.2$40
Supernus Pharmaceuticals, Inc.2$30
Inspire Medical Systems, Inc.2$29
Currax Pharmaceuticals LLC2$28
Octapharma USA, Inc.1$25
CSL Behring1$23
Arbor Pharmaceuticals, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,257 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$172,322
Medicare patients
347
Services billed
921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)25$63,838
Emgality PenGalcanezumab-Gnlm27$37,356
Aimovig AutoinjectorErenumab-Aooe16$28,274
Nurtec OdtRimegepant Sulfate16$27,837
Ajovy AutoinjectorFremanezumab-Vfrm11$12,335
Rivastigmine18$6,529
Levetiracetam81$4,484
Memantine Hcl118$4,102
Dimethyl Fumarate17$3,094
Lacosamide30$3,068
Carbidopa-LevodopaCarbidopa/Levodopa60$2,315
Memantine Hcl ErMemantine Hcl24$2,247
Carbamazepine14$2,242
Donepezil Hcl144$2,230
Gabapentin69$1,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$462$27,83716 claims
Upsher-smith Laboratories LLCTopiramate$216$37332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.

Other neurology in Auburn Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →